Mattel launches Barbie with Type 1 diabetes and a glucose monitor
Mattel announced the newest member of its Barbie Fashionistas line on Tuesday, saying that it not only lets children see themselves in the doll, but also encourages play "that extends beyond a child's own lived experience." The doll has a continuous glucose monitor attached to her arm and an insulin pump attached to her waist.
Krista Berger, senior vice president for Barbie and global head of dolls, said in a news release that the doll "marks an important step in our commitment to inclusivity."
"Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love," Berger said.
The Mayo Clinic defines Type 1 diabetes as a chronic condition that results when a person's pancreas creates little to no insulin, the hormone that helps glucose get into cells, where it's broken down. A glucose monitor allows someone with the condition to keep track of their sugar levels and inject insulin to help their body process glucose.
An insulin pump is a wearable device that allows for an easy supply of insulin into the body.
More than 18,000 young people under the age of 20 were diagnosed with Type 1 diabetes in the U.S. last year, according to the Centers for Disease Control and Prevention. The agency reported that there's been about a 2% increase per year in diagnosed cases between 2002 and 2018.
Barbie partnered with the nonprofit organization Breakthrough T1D in the development of its new doll and to ensure an accurate reflection of the devices, the release said. Breakthrough T1D CEO Aaron J. Kowalski said he was "thrilled" when the company proposed a collaboration.
"I have lived with T1D since I was 13, and my brother since he was 3, so this partnership is deeply personal – it means the world to be part of bringing greater visibility to a condition that affects so many families," Kowalski said.
A link to buy the doll on Mattel's website appears to already have reviews from parents who were sent the doll, as the website notes the reviews are "incentivized."
One parent wrote that they gave the doll to their 7-year-old daughter and it opened up a conversation about diabetes. Another parent called it a "great addition" to the Barbie brand.
"We have a close family friend who is T1D, so this was an excellent opportunity to explain what each item was and what it does to help keep people safe and healthy," the review said.
This article was originally published on NBCNews.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
5 days ago
Taliban say efforts to release a British couple from Afghan prison not yet complete
ISLAMABAD -- The Taliban said Wednesday that efforts to free a British couple from an Afghan prison are not yet complete and denied that their rights were being violated despite concerns from their families and U.N. officials. Peter and Barbie Reynolds, who are in their 70s, were arrested in early February after being taken from their home in central Bamiyan province to the capital, Kabul. The husband and wife run an organization that provides education and training programs. Family members in the U.K. have said they are being mistreated and held on undisclosed charges. U.N. human rights experts on Monday called for the couple's release, warning their physical and mental health was deteriorating rapidly and that they were at risk of irreparable harm or even death. The Taliban's Foreign Minister Amir Khan Muttaqi rejected concerns about rights violations. 'They are in constant contact with their families,' Muttaqi told reporters at a media briefing in Kabul. 'Consular services are available. Efforts are underway to secure their release. These steps have not yet been completed. Their human rights are being respected. They are being given full access to treatment, contact and accommodation.' He did not say what steps were being taken to secure their release. According to the U.N. experts, the couple's spell in detention included time in a maximum-security facility and later in underground cells, without sunlight, before being moved to above-ground cells at the General Directorate of Intelligence in Kabul. Peter needs heart medication and, during his detention, has had two eye infections and intermittent tremors in his head and down his left arm. He recently collapsed, the experts added, while Barbie suffers from anaemia and remains weak. Officials from the U.K. Foreign Ministry visited the couple on July 17, family members said. Peter and Barbie have no bed or furniture and sleep on a mattress on the floor, the family said in a statement Sunday. Peter's face is red, peeling and bleeding, likely due to the return of skin cancer that urgently needs removing. 'We, their four adult children, have written privately to the Taliban leadership twice, pleading for them to uphold their beliefs of compassion, mercy, fairness, and human dignity," the children added.
San Francisco Chronicle
5 days ago
- San Francisco Chronicle
Taliban say efforts to release a British couple from Afghan prison not yet complete
ISLAMABAD (AP) — The Taliban said Wednesday that efforts to free a British couple from an Afghan prison are not yet complete and denied that their rights were being violated despite concerns from their families and U.N. officials. Peter and Barbie Reynolds, who are in their 70s, were arrested in early February after being taken from their home in central Bamiyan province to the capital, Kabul. The husband and wife run an organization that provides education and training programs. Family members in the U.K. have said they are being mistreated and held on undisclosed charges. U.N. human rights experts on Monday called for the couple's release, warning their physical and mental health was deteriorating rapidly and that they were at risk of irreparable harm or even death. The Taliban's Foreign Minister Amir Khan Muttaqi rejected concerns about rights violations. 'They are in constant contact with their families,' Muttaqi told reporters at a media briefing in Kabul. 'Consular services are available. Efforts are underway to secure their release. These steps have not yet been completed. Their human rights are being respected. They are being given full access to treatment, contact and accommodation.' He did not say what steps were being taken to secure their release. According to the U.N. experts, the couple's spell in detention included time in a maximum-security facility and later in underground cells, without sunlight, before being moved to above-ground cells at the General Directorate of Intelligence in Kabul. Peter needs heart medication and, during his detention, has had two eye infections and intermittent tremors in his head and down his left arm. He recently collapsed, the experts added, while Barbie suffers from anaemia and remains weak. Officials from the U.K. Foreign Ministry visited the couple on July 17, family members said. Peter and Barbie have no bed or furniture and sleep on a mattress on the floor, the family said in a statement Sunday. Peter's face is red, peeling and bleeding, likely due to the return of skin cancer that urgently needs removing. 'We, their four adult children, have written privately to the Taliban leadership twice, pleading for them to uphold their beliefs of compassion, mercy, fairness, and human dignity," the children added.
Business Wire
17-07-2025
- Business Wire
Digostics Announces University Trial of New At-home Type 1 Diabetes Test Underway
OXFORD, England--(BUSINESS WIRE)--Researchers have initiated an evaluation of a new at-home test to diagnose and monitor early stages of type 1 diabetes (T1D), based on blood glucose levels. The test would be used in individuals who have already tested positive for T1D autoantibodies to identify where they may be in their early-stage T1D progression. The trial, which is funded by Breakthrough T1D (formerly JDRF) the leading global T1D research and advocacy organization, will assess the accuracy, reproducibility, and acceptability of the GTT@home Oral Glucose Tolerance Test (OGTT) compared to in-clinic OGTTs. The results of the trial will inform future regulatory submissions for GTT@home use in T1D, which already has regulatory approval in the UK, Europe and other regions for other types of diabetes. GTT@home is an OGTT developed by British diabetes home-testing company Digostics that uses finger-prick blood samples to measure how well the body processes glucose. The test, being studied at Yale School of Medicine in New Haven, Conn., has been shown to be as accurate as lab-based OGTTs when used in adults with glucose intolerance, type 2 diabetes, or in pregnant individuals to diagnosis gestational diabetes. The GTT@home test has successfully been implemented in several UK NHS Trusts to screen for gestational diabetes in pregnancy. Dr. Jennifer Sherr, Professor of Pediatric Endocrinology and the Medical Director of Pediatric Diabetes at Yale School of Medicine and co-lead principal investigator of the trial, said: 'As the presence of diabetes autoantibodies foretells an eventual diagnosis of T1D, it is critical to conduct an OGTT to stage the disease, which helps predict the risk of progression over time. Yet, in the current paradigm this requires coming to a clinical center or laboratory and getting venous blood draws. Despite knowing there is an increased risk of diabetes many individuals struggle to undergo an OGTT for staging, or repeat the test to permit ongoing monitoring. An at-home OGTT would alleviate this barrier. The ability to have those at risk use a product that is simple, requires fingerpricks instead of venous draws, and can be done within a person's own home at a date and time that is convenient for them would be a fantastic step forward for both patients and providers.' T1D can be diagnosed at any age, and it is the most common childhood autoimmune disease, affecting around one in 350 children. In T1D the body's immune system attacks and destroys the insulin-producing cells in the pancreas, resulting in elevated blood glucose levels. It affects every aspect of health and well-being and results in lifelong insulin dependence and an increased risk of major health problems such as heart disease, blindness, and kidney failure. In 40% or more of children the diagnosis of T1D is not made until the child has become severely unwell and presents with metabolic decompensation, which is known as diabetic ketoacidosis (DKA), a life-threatening diabetes complication. Dr. Raquel Lopez-Diez, Scientist at Breakthrough T1D commented, 'Breakthrough T1D is excited to fund this important work with Yale University School of Medicine to explore an at-home alternative to OGTT for glycemic monitoring in the early stages of type 1 diabetes. Traditional in-clinic OGTTs are time-consuming, can be challenging to navigate for younger individuals, and require significant clinic resources. As new therapies emerge that can delay and, hopefully, one day prevent the progression of type 1 diabetes, it is critical to have the tools to accurately and reliably monitor and diagnose the early stages of the disease. A validated at-home testing approach would represent a major breakthrough. We look forward to seeing the results of this important study.' T1D develops in stages over time, and early stages can be detected through a simple blood test. In stage 1 the body develops islet autoantibodies but the blood glucose levels are still normal. In stage 2, islet autoantibodies are present and individuals experience abnormal blood glucose or dysglycemia, and by stage 3 an individual has the clinical diagnosis of T1D and symptoms may begin to appear due to significant loss of insulin-producing cells. The OGTT is the gold-standard test recommended for defining the stage of T1D a person is experiencing, and it is the most sensitive test for monitoring T1D stages 1 and 2. Hospital-based OGTTs are often not well tolerated because they require placement of an intravenous line inserted into the vein or multiple blood draws, as several blood samples taken over 2-hours in a healthcare setting. Study lead Dr. Alfonso Galderisi, Associate Professor of Pediatrics at Yale School of Medicine, confirmed that the study will recruit 60 patients aged eight and over. 'To understand the ease of conducting the test, participants will complete an unsupervised GTT@home test. Five to seven days later, participants will come to our research unit and we will conduct the standard of care OGTT alongside a supervised GTT@home, with the results of the two tests compared to assess accuracy. We will also be interviewing participants to assess their perception of the two methods used to conduct OGTTs.' Glucose tolerance tests are performed in the morning after an overnight fast. The GTT@home test kit contains the test device, finger prickers for blood sample collection, a preformulated glucose drink, and detailed instructions. The process begins with an initial finger prick blood sample, followed by the consumption of the glucose drink. Two hours later, a second blood sample is taken. With standard clinic-based OGTTs, individuals need to travel to a clinic early in the morning and then undergo the two blood draws two hours apart and have an IV inserted. The GTT@home device analyses blood samples shortly after completion of the test and shares results in a timely manner directly with the study teams or clinician. Expedited analysis of samples eliminates the risk of sample degradation that can affect hospital-based OGTTs when samples are not sent to the lab immediately, improving diagnostic reliability. "The support from Breakthrough T1D and the team at Yale School of Medicine underscores once again the huge potential for our at-home OGTT for use in T1D," said James Jackson, CEO and Founder of Digostics. "We are working closely with the Yale study team to support this trial.'
